Streetbeat News

Regulatory

BAH

Booz Allen Hamilton (NYSE:BAH) has been awarded a $550 million contract by the U.S. Department of Energy's ARPA-E to support the advancement of innovative energy technologies. This ten-year contract aims to generate, store, and use energy in new ways to reduce U.S. emissions, improve energy efficiency, and enhance the power grid's resiliency. Booz Allen's role includes identifying energy challenges, supporting an innovation ecosystem, and de-risking technologies for long-term funding. The company's extensive experience with government ARPA programs and its corporate venture capital arm, Booz Allen Ventures, positions it as a key partner in driving energy innovation.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:05 pm

PLBY

PLBY Group, Inc. (NASDAQ:PLBY) announced it will restate its Q2 and Q3 2023 financials due to accounting errors related to an impaired Chinese license contract and commission expense adjustments. The restatements are expected to decrease net loss, increase Adjusted EBITDA, decrease total liabilities, with no impact on revenue, cash flows, liquidity, or future operations. The company will report its Q4 and full year 2023 financial results on March 27, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:04 pm

MDAI

Spectral AI, Inc. (NASDAQ:MDAI) has announced a new contract with the Defense Health Agency and the US Army Medical Material Development Activity valued at over $500,000 for the development of DeepView SnapShot® M, a handheld version of its DeepView Wound Imaging System. This contract adds to previous U.S. Government awards, bringing the total funding for DeepView SnapShot® M to over $6 million. The funding aims to optimize the device for combat readiness and expand its use in home health care, reinforcing Spectral AI's role in AI-driven healthcare innovation.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 12:03 pm

NRXP

NRx Pharmaceuticals is considering a reverse stock split to comply with Nasdaq listing requirements. This action may also involve a change in the company's name and CUSIP number. Additionally, the company has hired attorneys to address and prevent naked short positions in its securities.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:57 am

AUTL

Autolus Therapeutics' Nucleus manufacturing facility in Stevenage has received Manufacturer's Importation Authorization from the MHRA following a recent GMP inspection. This authorization, effective March 18, enables the facility to manufacture for global commercial and clinical product supply.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:13 am

ENVB

Enveric Biosciences announced that the US Patent and Trademark Office issued a patent for 'Multi-substituent Psilocybin Derivatives' on March 5 and is expected to issue another patent for 'Nitrilated Psilocybin Derivatives' on March 19. These patents represent significant advancements in the company's psychedelic compound development efforts.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:10 am

BCDA

BioCardia's stock price increased following the announcement that the Centers for Medicare & Medicaid Services (CMS) approved reimbursement coverage for its CardiAMP cell therapy Phase III heart failure study.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:06 am

BCDA

BioCardia has received CMS approval for coverage of its CardiAMP Cell Therapy Phase III study in heart failure, potentially accelerating patient enrollment and advancing the therapy's development.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:04 am

ADM

Archer-Daniels-Midland (ADM) announced a correction of historical financial information for specific segments and a plan to remediate material weaknesses. This move aims to enhance financial transparency and accuracy.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:03 am

KALV

KalVista Pharmaceuticals has received the Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency for Sebetralstat, a treatment for Hereditary Angioedema.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:38 am